샘플 요청 목록

 카트 문의
시장보고서
상품코드
1644055

세계의 파마 4.0 시장

Pharma 4.0
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 193 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

파마 4.0 세계 시장, 2030년까지 403억 달러에 달할 전망

2024년에 137억 달러로 추정되는 Pharma 4.0 세계 시장은 2024년부터 2030년까지 연평균 19.7%로 성장하여 2030년에는 403억 달러에 달할 것으로 예상됩니다. 본 보고서에서 분석한 부문 중 하나인 Pharma 4.0 소프트웨어는 CAGR 17.8%를 기록하여 분석 기간 종료 시점에 219억 달러에 달할 것으로 예상됩니다. Pharma 4.0 서비스 부문의 성장률은 분석 기간 동안 CAGR 22.3%로 추정됩니다.

미국 시장은 36억 달러, 중국은 CAGR 18.7%로 성장 전망

미국의 제약 4.0 시장은 2024년 36억 달러로 추정됩니다. 세계 2위의 경제 대국인 중국은 2030년까지 62억 달러의 시장 규모에 도달할 것으로 예상되며, 2024-2030년 분석 기간 동안 18.7% CAGR을 기록할 것으로 예상됩니다. 다른 주목할 만한 지역 시장으로는 일본과 캐나다가 있으며, 분석 기간 동안 각각 17.8% 및 17.3%의 CAGR로 성장할 것으로 예상됩니다. 유럽에서는 독일이 약 14.7%의 CAGR로 성장할 것으로 예상됩니다.

세계 Pharma 4.0 시장 동향 및 촉진요인 정리

Pharma 4.0이란 무엇이며, 제약 업계에 어떤 혁명을 불러일으키고 있는가?

Pharma 4.0은 제약 산업의 패러다임 전환을 상징하며, 인공지능(AI), 머신러닝(ML), 사물인터넷(IoT), 블록체인 등 첨단 기술을 활용하여 연결된 지능형 자동화된 생태계를 구축합니다. 인더스트리 4.0의 원칙에 기반한 Pharma 4.0은 의약품 제조 및 운영을 현대화하고 효율성, 규정 준수 및 품질 관리를 강화하는 것을 목표로 합니다. 이 프레임워크는 스마트 제조, 디지털화된 공급망, 예측 분석을 통합하여 생산 공정에서 실시간 의사결정과 민첩성을 향상시킬 수 있도록 지원합니다. 또한, Pharma 4.0은 환자 개개인의 요구에 맞는 정확하고 효율적인 의약품 제조를 가능하게 하는 맞춤형 의료에 대한 수요 증가에 대응하고 있습니다. 전 세계 헬스케어 시스템이 비용 효율적인 솔루션과 신약 출시 시간 단축에 대한 요구가 증가함에 따라 제약 4.0은 제약 분야 혁신의 초석이 되고 있습니다.

기술 발전은 제약 4.0의 채택을 어떻게 형성하고 있는가?

AI와 ML은 제조 장비의 예지보전을 촉진하고, 생산 일정을 최적화하며, 잠재적인 품질 문제가 심각해지기 전에 식별할 수 있는 AI와 ML이 최전선에 있으며, IoT와 센서 기술은 생산 환경을 실시간으로 모니터링하고 온도와 습도 변수를 정밀하게 제어할 수 있게 해줍니다. 온도, 습도 등의 변수를 정확하게 제어할 수 있습니다. 블록체인 기술은 공급망의 투명성과 안전성을 높이고, 원자재에서 최종사용자까지 의약품의 추적성을 가능하게 합니다. 클라우드 컴퓨팅 및 데이터 분석 플랫폼은 대량의 데이터를 원활하게 통합하고 분석하여 제약회사가 데이터 기반 의사결정을 내릴 수 있도록 돕습니다. 또한, 디지털 트윈(물리적 프로세스의 가상 복제본)은 실제 생산을 중단하지 않고도 제조 시스템을 테스트하고 최적화할 수 있어 다운타임과 비용을 절감할 수 있습니다.

파마 4.0의 도입을 촉진하는 산업 및 이해관계자는 누구인가?

Pharma 4.0의 도입은 제약사, CDMO, 규제기관이 주도하고 있습니다. 제약사들은 시설 현대화, 폐기물 감소, 생산성 향상을 위해 이러한 기술을 활용하고 있습니다. 의약품 제조 아웃소싱에서 중요한 역할을 하는 CDMO는 효율적이고 컴플라이언스를 준수하는 프로세스를 요구하는 고객의 요구에 부응하기 위해 Pharma 4.0 솔루션을 통합하고 있으며, FDA 및 EMA와 같은 규제 기관은 컴플라이언스 및 추적성을 개선하기 위해 디지털 기술을 도입하고 있습니다. 을 개선하기 위해 디지털 기술 도입을 장려하고 있습니다. 또한, 맞춤형 의료와 바이오의약품의 발전으로 인해 제약 4.0이 가능하게 하는 유연한 제조 시스템에 대한 수요가 급증하고 있습니다. 주요 응용 분야로는 공정 자동화, 실시간 품질 보증, 예지보전 등이 있습니다. 의약품의 복잡성과 엔드 투 엔드 추적 가능성에 대한 필요성이 전체 밸류체인에서 Pharma 4.0 솔루션의 채택을 더욱 촉진하고 있습니다.

Pharma 4.0 시장의 성장을 촉진하는 주요 요인은 무엇인가?

Pharma 4.0 시장의 성장은 기술 발전, 규제 프레임워크의 진화, 업계 요구의 변화 등 여러 요인에 의해 촉진되고 있습니다. 맞춤형 정밀 의약품에 대한 수요가 증가함에 따라 제약사들은 Pharma 4.0을 활용한 유연하고 자동화된 제조 시스템을 채택하고 있습니다. 추적성 및 컴플라이언스에 대한 규제 요건이 강화됨에 따라 기업들은 블록체인과 IoT 솔루션의 통합을 요구하고 있습니다. 또한, 복잡한 생물학적 제제 및 바이오시밀러의 확산으로 인해 고도의 품질 관리 조치가 필요하며, 이는 AI 기반 분석을 통해 실현될 수 있습니다. 데이터 기반 의사결정으로의 전환은 클라우드 컴퓨팅 및 엣지 컴퓨팅의 채택 증가와 함께 시장 성장을 더욱 가속화하고 있습니다. 또한, 의약품 제조의 지속가능성과 에너지 효율성에 대한 관심이 높아지면서 스마트하고 자원에 최적화된 생산 시스템에 대한 수요를 촉진하고 있습니다. 기술 제공업체와 제약사 간의 협력과 디지털 전환에 대한 투자 증가는 Pharma 4.0 시장의 꾸준한 성장을 보장하고 있습니다.

부문

컴포넌트(Pharma 4.0 소프트웨어, Pharma 4.0 서비스), 기술(인공지능·머신러닝 기술, 빅데이터 분석 기술, IoT 기술, 블록체인 기술, 기타 기술), 용도(신약개발 용도, 제조 용도, 공급망 관리 용도, 기타 용도), 최종 용도(제약·바이오 기업 최종 용도, CRO·CDMO 최종 용도, 헬스케어 공급자 최종 용도) 공급망 관리 용도, 기타 용도)

조사 대상 기업 사례(주목 25개사)

  • Amazon Web Services, Inc.
  • Aspen Technology, Inc.
  • Cisco Systems, Inc.
  • GE Healthcare
  • IBM Corporation
  • Lighthouse Worldwide Solutions Inc.
  • nexocode
  • Oracle Corporation
  • Tulip Interfaces, Inc.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 성장 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 기타 지역

제4장 경쟁

ksm 25.02.14

Global Pharma 4.0 Market to Reach US$40.3 Billion by 2030

The global market for Pharma 4.0 estimated at US$13.7 Billion in the year 2024, is expected to reach US$40.3 Billion by 2030, growing at a CAGR of 19.7% over the analysis period 2024-2030. Pharma 4.0 Software, one of the segments analyzed in the report, is expected to record a 17.8% CAGR and reach US$21.9 Billion by the end of the analysis period. Growth in the Pharma 4.0 Services segment is estimated at 22.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.6 Billion While China is Forecast to Grow at 18.7% CAGR

The Pharma 4.0 market in the U.S. is estimated at US$3.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$6.2 Billion by the year 2030 trailing a CAGR of 18.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 17.8% and 17.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.7% CAGR.

Global Pharma 4.0 Market - Key Trends & Drivers Summarized

What Is Pharma 4.0 and How Is It Revolutionizing the Pharmaceutical Industry?

Pharma 4.0 represents a paradigm shift in the pharmaceutical industry, leveraging advanced technologies such as artificial intelligence (AI), machine learning (ML), Internet of Things (IoT), and blockchain to create a connected, intelligent, and automated ecosystem. Rooted in the principles of Industry 4.0, Pharma 4.0 aims to modernize pharmaceutical manufacturing and operations, ensuring enhanced efficiency, compliance, and quality control. The framework integrates smart manufacturing, digitalized supply chains, and predictive analytics to enable real-time decision-making and greater agility in production processes. Pharma 4.0 also addresses the growing need for personalized medicine, enabling precise and efficient drug production tailored to individual patient needs. As global healthcare systems face increasing demands for cost-effective solutions and faster time-to-market for new drugs, Pharma 4.0 is rapidly becoming the cornerstone of innovation in the pharmaceutical sector.

How Are Technological Advancements Shaping the Adoption of Pharma 4.0?

The adoption of Pharma 4.0 has been significantly accelerated by advancements in enabling technologies. AI and ML are at the forefront, driving predictive maintenance in manufacturing equipment, optimizing production schedules, and identifying potential quality issues before they escalate. IoT and sensor technologies enable real-time monitoring of production environments, ensuring precise control over variables such as temperature and humidity. Blockchain technology enhances supply chain transparency and security, enabling traceability of pharmaceutical products from raw materials to end-users. Cloud computing and data analytics platforms facilitate seamless integration and analysis of large volumes of data, empowering pharmaceutical companies to make data-driven decisions. Furthermore, digital twins—virtual replicas of physical processes—allow for testing and optimization of manufacturing systems without disrupting actual production, thereby reducing downtime and costs.

Which Industries and Stakeholders Are Driving the Adoption of Pharma 4.0?

Pharma 4.0 adoption is being led by pharmaceutical manufacturers, contract development and manufacturing organizations (CDMOs), and regulatory bodies. Manufacturers are leveraging these technologies to modernize facilities, reduce waste, and enhance productivity. CDMOs, which play a critical role in outsourced drug production, are integrating Pharma 4.0 solutions to meet client demands for efficient and compliant processes. Regulatory bodies such as the FDA and EMA are encouraging the adoption of digital technologies to improve compliance and traceability. In addition, the push for personalized medicine and biologics has created a surge in demand for flexible manufacturing systems that Pharma 4.0 enables. Key applications include process automation, real-time quality assurance, and predictive maintenance. The increasing complexity of pharmaceutical products and the need for end-to-end traceability are further driving the adoption of Pharma 4.0 solutions across the value chain.

What Are the Key Drivers Fueling the Growth of the Pharma 4.0 Market?

The growth in the Pharma 4.0 market is driven by several factors, including advancements in technology, evolving regulatory frameworks, and changing industry needs. The rising demand for personalized and precision medicines has prompted pharmaceutical companies to adopt flexible and automated manufacturing systems enabled by Pharma 4.0. Increasing regulatory requirements for traceability and compliance are compelling firms to integrate blockchain and IoT solutions. Additionally, the growing prevalence of complex biologics and biosimilars necessitates advanced quality control measures, which are achievable through AI-driven analytics. The shift toward data-driven decision-making, coupled with the rising adoption of cloud and edge computing, has further accelerated market growth. Furthermore, the push for sustainability and energy efficiency in pharmaceutical manufacturing is driving demand for smart, resource-optimized production systems. The increasing collaboration between technology providers and pharmaceutical companies, along with rising investments in digital transformation, is ensuring steady growth in the Pharma 4.0 market.

SCOPE OF STUDY:

The report analyzes the Pharma 4.0 market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Component (Pharma 4.0 Software, Pharma 4.0 Services); Technology (Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology, Other Technologies); Application (Drug Discovery & Development Application, Manufacturing Application, Supply Chain Management Application, Other Applications); End-Use (Pharma & Biotech Companies End-Use, CRO & CDMO End-Use, Healthcare Providers End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 25 Featured) -

  • Amazon Web Services, Inc.
  • Aspen Technology, Inc.
  • Cisco Systems, Inc.
  • GE Healthcare
  • IBM Corporation
  • Lighthouse Worldwide Solutions Inc.
  • nexocode
  • Oracle Corporation
  • Tulip Interfaces, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Economic Frontiers: Trends, Trials & Transformations
    • Pharma 4.0 - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Adoption of Smart Manufacturing Systems in Pharmaceuticals Propels Growth
    • Increasing Use of IoT for Real-Time Monitoring Drives Pharma 4.0 Adoption
    • AI and Machine Learning Enable Predictive Quality Control, Fueling Demand
    • Expansion of Continuous Manufacturing Processes Enhances Market Potential
    • Integration of Blockchain in Pharma Supply Chains Boosts Market Growth
    • Digital Twins for Drug Development Propel Pharma 4.0 Deployment
    • Advancements in Robotics Drive Efficiency in Pharmaceutical Manufacturing
    • Rising Demand for Personalized Medicine Fuels Adoption of Pharma 4.0 Technologies
    • Increased Focus on Data Analytics Improves Decision-Making in Pharma Operations
    • Expansion of Cloud-Based Pharma Solutions Drives Market Growth
    • AR and VR Technologies Revolutionize Pharma Training and Operations
    • Predictive Maintenance Enhances Equipment Management Efficiency
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Pharma 4.0 Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Pharma 4.0 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Pharma 4.0 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Pharma 4.0 Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Pharma 4.0 Software by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Pharma 4.0 Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Pharma 4.0 Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Supply Chain Management Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Supply Chain Management Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Drug Discovery & Development Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Drug Discovery & Development Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Manufacturing Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Manufacturing Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Pharma & Biotech Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for CRO & CDMO End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for CRO & CDMO End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Healthcare Providers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Healthcare Providers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Artificial Intelligence & Machine Learning Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Artificial Intelligence & Machine Learning Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Big Data Analytics Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Big Data Analytics Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for IoT Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for IoT Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Blockchain Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 29: World 6-Year Perspective for Blockchain Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 30: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 31: World 6-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Pharma 4.0 Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Pharma 4.0 by Component - Pharma 4.0 Software and Pharma 4.0 Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA 6-Year Perspective for Pharma 4.0 by Component - Percentage Breakdown of Value Sales for Pharma 4.0 Software and Pharma 4.0 Services for the Years 2025 & 2030
    • TABLE 34: USA Recent Past, Current & Future Analysis for Pharma 4.0 by Application - Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: USA 6-Year Perspective for Pharma 4.0 by Application - Percentage Breakdown of Value Sales for Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application for the Years 2025 & 2030
    • TABLE 36: USA Recent Past, Current & Future Analysis for Pharma 4.0 by End-Use - Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: USA 6-Year Perspective for Pharma 4.0 by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use for the Years 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Pharma 4.0 by Technology - Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA 6-Year Perspective for Pharma 4.0 by Technology - Percentage Breakdown of Value Sales for Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies for the Years 2025 & 2030
  • CANADA
    • TABLE 40: Canada Recent Past, Current & Future Analysis for Pharma 4.0 by Component - Pharma 4.0 Software and Pharma 4.0 Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Canada 6-Year Perspective for Pharma 4.0 by Component - Percentage Breakdown of Value Sales for Pharma 4.0 Software and Pharma 4.0 Services for the Years 2025 & 2030
    • TABLE 42: Canada Recent Past, Current & Future Analysis for Pharma 4.0 by Application - Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Canada 6-Year Perspective for Pharma 4.0 by Application - Percentage Breakdown of Value Sales for Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application for the Years 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Pharma 4.0 by End-Use - Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada 6-Year Perspective for Pharma 4.0 by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use for the Years 2025 & 2030
    • TABLE 46: Canada Recent Past, Current & Future Analysis for Pharma 4.0 by Technology - Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Canada 6-Year Perspective for Pharma 4.0 by Technology - Percentage Breakdown of Value Sales for Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies for the Years 2025 & 2030
  • JAPAN
    • Pharma 4.0 Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 48: Japan Recent Past, Current & Future Analysis for Pharma 4.0 by Component - Pharma 4.0 Software and Pharma 4.0 Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Japan 6-Year Perspective for Pharma 4.0 by Component - Percentage Breakdown of Value Sales for Pharma 4.0 Software and Pharma 4.0 Services for the Years 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Pharma 4.0 by Application - Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan 6-Year Perspective for Pharma 4.0 by Application - Percentage Breakdown of Value Sales for Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application for the Years 2025 & 2030
    • TABLE 52: Japan Recent Past, Current & Future Analysis for Pharma 4.0 by End-Use - Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Japan 6-Year Perspective for Pharma 4.0 by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use for the Years 2025 & 2030
    • TABLE 54: Japan Recent Past, Current & Future Analysis for Pharma 4.0 by Technology - Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Japan 6-Year Perspective for Pharma 4.0 by Technology - Percentage Breakdown of Value Sales for Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies for the Years 2025 & 2030
  • CHINA
    • Pharma 4.0 Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Pharma 4.0 by Component - Pharma 4.0 Software and Pharma 4.0 Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China 6-Year Perspective for Pharma 4.0 by Component - Percentage Breakdown of Value Sales for Pharma 4.0 Software and Pharma 4.0 Services for the Years 2025 & 2030
    • TABLE 58: China Recent Past, Current & Future Analysis for Pharma 4.0 by Application - Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: China 6-Year Perspective for Pharma 4.0 by Application - Percentage Breakdown of Value Sales for Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application for the Years 2025 & 2030
    • TABLE 60: China Recent Past, Current & Future Analysis for Pharma 4.0 by End-Use - Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: China 6-Year Perspective for Pharma 4.0 by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use for the Years 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Pharma 4.0 by Technology - Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China 6-Year Perspective for Pharma 4.0 by Technology - Percentage Breakdown of Value Sales for Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies for the Years 2025 & 2030
  • EUROPE
    • Pharma 4.0 Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 64: Europe Recent Past, Current & Future Analysis for Pharma 4.0 by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 65: Europe 6-Year Perspective for Pharma 4.0 by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 66: Europe Recent Past, Current & Future Analysis for Pharma 4.0 by Component - Pharma 4.0 Software and Pharma 4.0 Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Europe 6-Year Perspective for Pharma 4.0 by Component - Percentage Breakdown of Value Sales for Pharma 4.0 Software and Pharma 4.0 Services for the Years 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Pharma 4.0 by Application - Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe 6-Year Perspective for Pharma 4.0 by Application - Percentage Breakdown of Value Sales for Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application for the Years 2025 & 2030
    • TABLE 70: Europe Recent Past, Current & Future Analysis for Pharma 4.0 by End-Use - Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Europe 6-Year Perspective for Pharma 4.0 by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use for the Years 2025 & 2030
    • TABLE 72: Europe Recent Past, Current & Future Analysis for Pharma 4.0 by Technology - Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Europe 6-Year Perspective for Pharma 4.0 by Technology - Percentage Breakdown of Value Sales for Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies for the Years 2025 & 2030
  • FRANCE
    • Pharma 4.0 Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 74: France Recent Past, Current & Future Analysis for Pharma 4.0 by Component - Pharma 4.0 Software and Pharma 4.0 Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France 6-Year Perspective for Pharma 4.0 by Component - Percentage Breakdown of Value Sales for Pharma 4.0 Software and Pharma 4.0 Services for the Years 2025 & 2030
    • TABLE 76: France Recent Past, Current & Future Analysis for Pharma 4.0 by Application - Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: France 6-Year Perspective for Pharma 4.0 by Application - Percentage Breakdown of Value Sales for Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application for the Years 2025 & 2030
    • TABLE 78: France Recent Past, Current & Future Analysis for Pharma 4.0 by End-Use - Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: France 6-Year Perspective for Pharma 4.0 by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use for the Years 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Pharma 4.0 by Technology - Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France 6-Year Perspective for Pharma 4.0 by Technology - Percentage Breakdown of Value Sales for Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies for the Years 2025 & 2030
  • GERMANY
    • Pharma 4.0 Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 82: Germany Recent Past, Current & Future Analysis for Pharma 4.0 by Component - Pharma 4.0 Software and Pharma 4.0 Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Germany 6-Year Perspective for Pharma 4.0 by Component - Percentage Breakdown of Value Sales for Pharma 4.0 Software and Pharma 4.0 Services for the Years 2025 & 2030
    • TABLE 84: Germany Recent Past, Current & Future Analysis for Pharma 4.0 by Application - Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Germany 6-Year Perspective for Pharma 4.0 by Application - Percentage Breakdown of Value Sales for Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application for the Years 2025 & 2030
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Pharma 4.0 by End-Use - Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany 6-Year Perspective for Pharma 4.0 by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use for the Years 2025 & 2030
    • TABLE 88: Germany Recent Past, Current & Future Analysis for Pharma 4.0 by Technology - Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Germany 6-Year Perspective for Pharma 4.0 by Technology - Percentage Breakdown of Value Sales for Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies for the Years 2025 & 2030
  • ITALY
    • TABLE 90: Italy Recent Past, Current & Future Analysis for Pharma 4.0 by Component - Pharma 4.0 Software and Pharma 4.0 Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Italy 6-Year Perspective for Pharma 4.0 by Component - Percentage Breakdown of Value Sales for Pharma 4.0 Software and Pharma 4.0 Services for the Years 2025 & 2030
    • TABLE 92: Italy Recent Past, Current & Future Analysis for Pharma 4.0 by Application - Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Italy 6-Year Perspective for Pharma 4.0 by Application - Percentage Breakdown of Value Sales for Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application for the Years 2025 & 2030
    • TABLE 94: Italy Recent Past, Current & Future Analysis for Pharma 4.0 by End-Use - Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Italy 6-Year Perspective for Pharma 4.0 by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use for the Years 2025 & 2030
    • TABLE 96: Italy Recent Past, Current & Future Analysis for Pharma 4.0 by Technology - Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Italy 6-Year Perspective for Pharma 4.0 by Technology - Percentage Breakdown of Value Sales for Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies for the Years 2025 & 2030
  • UNITED KINGDOM
    • Pharma 4.0 Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 98: UK Recent Past, Current & Future Analysis for Pharma 4.0 by Component - Pharma 4.0 Software and Pharma 4.0 Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: UK 6-Year Perspective for Pharma 4.0 by Component - Percentage Breakdown of Value Sales for Pharma 4.0 Software and Pharma 4.0 Services for the Years 2025 & 2030
    • TABLE 100: UK Recent Past, Current & Future Analysis for Pharma 4.0 by Application - Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: UK 6-Year Perspective for Pharma 4.0 by Application - Percentage Breakdown of Value Sales for Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application for the Years 2025 & 2030
    • TABLE 102: UK Recent Past, Current & Future Analysis for Pharma 4.0 by End-Use - Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 103: UK 6-Year Perspective for Pharma 4.0 by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use for the Years 2025 & 2030
    • TABLE 104: UK Recent Past, Current & Future Analysis for Pharma 4.0 by Technology - Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK 6-Year Perspective for Pharma 4.0 by Technology - Percentage Breakdown of Value Sales for Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 106: Rest of Europe Recent Past, Current & Future Analysis for Pharma 4.0 by Component - Pharma 4.0 Software and Pharma 4.0 Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Rest of Europe 6-Year Perspective for Pharma 4.0 by Component - Percentage Breakdown of Value Sales for Pharma 4.0 Software and Pharma 4.0 Services for the Years 2025 & 2030
    • TABLE 108: Rest of Europe Recent Past, Current & Future Analysis for Pharma 4.0 by Application - Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 109: Rest of Europe 6-Year Perspective for Pharma 4.0 by Application - Percentage Breakdown of Value Sales for Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application for the Years 2025 & 2030
    • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for Pharma 4.0 by End-Use - Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Rest of Europe 6-Year Perspective for Pharma 4.0 by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use for the Years 2025 & 2030
    • TABLE 112: Rest of Europe Recent Past, Current & Future Analysis for Pharma 4.0 by Technology - Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 113: Rest of Europe 6-Year Perspective for Pharma 4.0 by Technology - Percentage Breakdown of Value Sales for Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Pharma 4.0 Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 114: Asia-Pacific Recent Past, Current & Future Analysis for Pharma 4.0 by Component - Pharma 4.0 Software and Pharma 4.0 Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 115: Asia-Pacific 6-Year Perspective for Pharma 4.0 by Component - Percentage Breakdown of Value Sales for Pharma 4.0 Software and Pharma 4.0 Services for the Years 2025 & 2030
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Pharma 4.0 by Application - Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific 6-Year Perspective for Pharma 4.0 by Application - Percentage Breakdown of Value Sales for Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application for the Years 2025 & 2030
    • TABLE 118: Asia-Pacific Recent Past, Current & Future Analysis for Pharma 4.0 by End-Use - Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 119: Asia-Pacific 6-Year Perspective for Pharma 4.0 by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use for the Years 2025 & 2030
    • TABLE 120: Asia-Pacific Recent Past, Current & Future Analysis for Pharma 4.0 by Technology - Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 121: Asia-Pacific 6-Year Perspective for Pharma 4.0 by Technology - Percentage Breakdown of Value Sales for Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 122: Rest of World Recent Past, Current & Future Analysis for Pharma 4.0 by Component - Pharma 4.0 Software and Pharma 4.0 Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of World 6-Year Perspective for Pharma 4.0 by Component - Percentage Breakdown of Value Sales for Pharma 4.0 Software and Pharma 4.0 Services for the Years 2025 & 2030
    • TABLE 124: Rest of World Recent Past, Current & Future Analysis for Pharma 4.0 by Application - Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 125: Rest of World 6-Year Perspective for Pharma 4.0 by Application - Percentage Breakdown of Value Sales for Supply Chain Management Application, Other Applications, Drug Discovery & Development Application and Manufacturing Application for the Years 2025 & 2030
    • TABLE 126: Rest of World Recent Past, Current & Future Analysis for Pharma 4.0 by End-Use - Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 127: Rest of World 6-Year Perspective for Pharma 4.0 by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, CRO & CDMO End-Use and Healthcare Providers End-Use for the Years 2025 & 2030
    • TABLE 128: Rest of World Recent Past, Current & Future Analysis for Pharma 4.0 by Technology - Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of World 6-Year Perspective for Pharma 4.0 by Technology - Percentage Breakdown of Value Sales for Artificial Intelligence & Machine Learning Technology, Big Data Analytics Technology, IoT Technology, Blockchain Technology and Other Technologies for the Years 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제